Dasatinib Combination Therapy With the Smoothened (SMO) Inhibitor BMS-833923 in Chronic Myeloid Leukemia (CML)

Model scores of the 29,894 trials active now.

Model score 22% for any early termination, 6% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 29% of the time (655 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2013-04-30. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: bmsleukemiachemotherapytherapyto determine
  Phrases that lowered it: tolerabilitysafetybloodcardiovascularuse of
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 1/2 (raises risk) · Design
• Sponsor's past termination rate: 8.8% (raises risk) · Sponsor's track record
• Disease area, cancer: Yes (raises risk) · Disease area
• Design: single group (raises risk) · Design
• Number of arms: 4 (lowers risk) · Design
• Trials the sponsor started in the prior 2 years: 102 (lowers risk) · Sponsor's track record
• Drug's FAERS reports with a death: 24.3% (raises risk) · Drug's FDA history
• Sponsor's past trials: 273 (lowers risk) · Sponsor's track record
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Drug's FAERS reports marked serious: 94.1% (raises risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Has a data monitoring committee: No (lowers risk) · Design
• Collaborators: 0 (raises risk) · Design
• Drug's FAERS reports in the prior 12 months: 170 (raises risk) · Drug's FDA history
• Maximum age: not given (raises risk) · Who can join

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• A Phase 1B Study to Investigate the Safety and Preliminary Efficacy for the Combination of Dasatinib Plus Nivolumab in Patients With Chronic Myeloid Leukemia NCT02011945 · started 2014 · scored riskier than 44% of active trials completed
• Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response NCT01850004 · started 2014 · scored riskier than 81% of active trials completed
• Efficacy and Safety Study of Dasatinib in Patients With Chronic Myeloid Leukemia NCT00895297 · started 2010 · scored riskier than 69% of active trials terminated
• Phase 2 Dasatinib Combo With Smoothened (SMO) Antagonist (BMS-833923) NCT01357655 · started 2011 · scored riskier than 74% of active trials terminated
• Randomized Study Comparing the Effect of Dasatinib and Imatinib on Malignant Stem Cells in Chronic Myeloid Leukemia NCT00852566 · started 2009 · scored riskier than 54% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.